Americans pay more for medications than anybody else in the world. We’re the planet’s suckers: although everybody uses, by and large, the same meds, the drugs that carry the highest prices are — you ...

A popular zero-calorie sweetener in diet sodas and snacks reduced immunotherapy effectiveness in melanoma and non-small cell ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable ...

We recently published 13 Stocks That Jim Cramer Recently Talked About. Merck & Co., Inc. (NYSE:MRK) is one of the stocks Jim Cramer recently discussed.

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

The remainder of 2025 will be busy for Vir Biotechnology as it strives to successfully pivot to developing cancer and infectious disease therapies.

The firm is leveraging its expertise in the immuno-oncology space to expedite development of newer agents like the bispecific ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

Drug maker Merck announced Tuesday it will embark on an initiative to cut $3 billion in costs 2027, including an undisclosed ...

NovoCure faces margin pressure, slow launches, and adoption hurdles beyond GBM, despite revenue beats and pipeline hopes.